Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity
The antimuscarinic agent ipratropium bromide has been reported to cause paradoxical bronchoconstriction when administered by nebuliser to patients with asthma.'-3 The mechanism of this bronchoconstriction has not been clearly defined, although an idiosyncratic response to the bromide moiety was suggested from a study of one patient.2 The importance of solution tonicitv with respect to this bronchoconstriction, however, has not been investigated. As commercially available ipratropium bromide solution is hypotonic, and inhalation of nebulised hypotonic solutions may produce bronchoconstriction in asthma,4-5 we decided to investigate the effect of solution tonicity on this paradoxical airway response.
Patients, methods, and results
Eight asthmatic subjects with marked non-specific airway reactivity were selected for study, and all were found to bronchoconstrict with nebulised ipratropium bromide. They subsequently participated in a double blind, placebo controlled, randomised study. On four separate days, after omitting their usual medication for at least six hours, each subject received one of four nebulised solutions: commercially available ipratropium bromide (0 025°) in hypotonic vehicle (osmolality 7-5 mmol (mosmol),jkg); the hypotonic vehicle alone (7-5 mmol 'kg); ipratropium bromide in isotonic vehicle (296 mmol 'kg); and nebulised isotonic 0-9 ',, sodium chloride alone (296 mmol 1kg). All solutions were nebulised using an Inspiron minijet nebuliser (Bard, Pennywell, Sunderland) at a flow of 8 1, min with a 4 ml starting volume. Patients inhaled the aerosols through a mouthpiece during tidal breathing for three minutes. Under these conditions approximately 1 ml of the test solution was delivered, on inspiration, by the nebuliser. Measurements were made of the forced expiratory volume in one second (FEV1) before and 2, 5, 10, 15, 30, and 45 minutes after nebulisation.
On a separate occasion each subject's non-specific bronchial reactivity was measured as the provocative concentration of methacholine required to produce a 20'i) fall in the FEV, (PC20).
Statistical analysis was by Student's t test and Duncan's multiple range test.
The patients' geometric mean PC20 was 0-22 g/l (range 0-10-0-50). There were no significant differences in the mean baseline FEV, values (litres) on any of the four separate days when the patients received either hypotonic ipratropium bromide (3-01 (SEM 0 26)), isotonic ipratropium bromide (2-95 (0-25)), hypotonic placebo (2-96 (0.23) ), or isotonic saline (3-13 (0 30)). Both hypotonic solutions caused bronchoconstriction, with maximum falls in FEV1 two minutes after nebulisation of 55-5 (SEM 5-5)%O with hypotonic placebo and 48-0 (5-2)0% with hypotonic ipratropium bromide (p<001; figure) . The bronchoconstriction with the hypotonic placebo was significantly greater than with the hypotonic ipratropium bromide at all time points (p < 0-05). In these patients with pronounced airway reactivity both isotonic ipratropium bromide and saline solutions caused small falls in FEV1 of 12-5 (SEM 6-1)0% and 8-4 (3-4)0' respectively (figure). These falls were significantly less at all time points when compared with the FEVy responses to the hypotonic solutions (p < 0.01).
+10. 
Comment
This study clearly shows that nebulised ipratropium bromide, as now marketed, causes bronchoconstriction in a group of asthmatic patients with pronounced non-specific airway reactivity. The bronchoconstriction was reproduced by the vehicle alone and could be largely attenuated by adding sodium chloride to render the solution isotonic. We therefore believe that the paradoxical airway response produced by commercially available ipratropium bromide nebuliser solution is due to its hypotonicity. These results are not consistent with an idiosyncratic response to the bromide moiety of this compound as suggested by Patel and Tullett.' In their study no details of the tonicity of the nebulised solutions were given. The recognised association between tonicity of nebulised solutions and bronchoconstriction in asthma suggests that hypotonicity is a more widely applicable mechanism to account for bronchoconstriction induced by nebulised ipratropium bromide.5 Thus while nebulisation of the currently available ipratropium bromide nebuliser solution may cause bronchoconstriction in asthma, reformulation as an isotonic solution would prevent this risk.
